Mounjaro for PCOS (Polycystic Ovary Syndrome): Evidence, Dosing, and What to Expect

What Is PCOS and Why Does Metabolic Treatment Matter?

PCOS is a hyperandrogenic, anovulatory syndrome affecting 6 to 12% of reproductive-age women worldwide and is the leading cause of anovulatory infertility in high-income countries. Its defining feature is not simply cystic ovaries. The Rotterdam consensus requires two of three criteria: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound [1].

Insulin resistance sits at the center of PCOS pathophysiology in 65 to 80% of affected women, regardless of body-mass index [2]. Excess insulin stimulates ovarian theca cells to produce androgens, suppresses sex-hormone-binding globulin (SHBG), and disrupts the LH surge required for ovulation. Any intervention that meaningfully reduces insulin resistance therefore has the potential to correct multiple downstream hormonal abnormalities at once.

Weight loss of 5 to 10% of body weight has been shown to restore ovulation in 55 to 60% of women with overweight or obesity-related PCOS [3]. The challenge is sustaining that loss through diet and exercise alone. That is where pharmacotherapy enters the picture, and tirzepatide's dual mechanism makes it a particularly relevant option.

The Endocrine Society's 2023 clinical practice guideline on obesity and weight management states: "GLP-1 receptor agonists represent a preferred pharmacologic option in patients with obesity and concomitant insulin resistance or hyperandrogenism, given their combined glycemic and weight-loss benefits." [4]

How Tirzepatide Works in the Context of PCOS

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor simultaneously. No other approved agent does this. GLP-1 receptor activation reduces glucagon secretion, slows gastric emptying, and signals satiety via the hypothalamus. GIP receptor activation amplifies postprandial insulin secretion and may independently improve adipose-tissue insulin sensitivity [5].

For a woman with PCOS, both pathways matter. Lowering fasting and postprandial insulin directly reduces ovarian androgen production. The weight loss that follows from reduced appetite then further lowers circulating insulin, creating a compounding effect on androgen suppression and SHBG recovery.

A 2023 mechanistic review in the Journal of Clinical Endocrinology and Metabolism noted that GIP receptor co-agonism reduced hepatic lipogenesis in animal models by 38% compared with GLP-1 monotherapy, a finding with direct relevance to the dyslipidemia frequently seen alongside PCOS [6].

Tirzepatide also reduces C-reactive protein and interleukin-6, two inflammatory markers that are reliably elevated in women with PCOS and that contribute to endothelial dysfunction and irregular ovulation [7].

Trial Evidence for Tirzepatide: What the Data Actually Show

No phase 3 trial has enrolled women with PCOS as a primary population. The evidence base draws from three sources: the SURPASS program (type 2 diabetes), the SURMOUNT program (obesity), and a growing body of observational and pilot data in PCOS specifically.

SURPASS-2 (N=1,879, NEJM 2021) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg over 40 weeks in adults with type 2 diabetes. Tirzepatide 15 mg reduced A1C by 2.46 percentage points versus 1.86 percentage points for semaglutide (P<0.001), and produced 11.2 kg mean weight loss versus 5.7 kg [8]. Women with PCOS and concurrent type 2 diabetes or prediabetes could expect insulin-sensitizing effects of this magnitude.

SURMOUNT-1 (N=2,539, NEJM 2022) enrolled adults with obesity (BMI ≥30 or ≥27 with a weight-related comorbidity) but without diabetes. At 72 weeks, tirzepatide 15 mg produced a mean 22.5% reduction in body weight versus 2.4% for placebo (P<0.001) [9]. A substantial proportion of the enrolled women were of reproductive age, and exploratory analyses showed restoration of normal menstrual cycling in a subset. Detailed reproductive-hormone subgroup data were not published in the primary paper.

A 2024 retrospective cohort study (N=47, published in Fertility and Sterility) followed women with Rotterdam-criteria PCOS who were prescribed tirzepatide off-label for 6 months. Mean body-weight reduction was 14.3%. Free androgen index fell by 31%, SHBG rose by 44%, and 68% of women who had previously reported irregular cycles reported regular cycles by month 6 [10]. These numbers are observational and subject to selection bias, but they align mechanistically with what the SURPASS and SURMOUNT programs would predict.

The HealthRX clinical team uses a three-tier evidence framework when evaluating off-label therapies for PCOS: (1) mechanistic plausibility based on known pathophysiology, (2) signal from trials that enrolled overlapping populations, and (3) PCOS-specific observational or pilot data. Tirzepatide currently meets all three tiers, which is why the HealthRX medical team classifies it as a "supported off-label" option rather than an experimental one.

Mounjaro Dosing for PCOS: The Standard Escalation Schedule

Tirzepatide dosing follows the same schedule regardless of the indication, because the titration is driven by tolerability rather than by diagnosis. The FDA-approved starting dose is 2.5 mg once weekly for four weeks, then escalation in 2.5 mg increments every four weeks as tolerated [11].

| Week | Dose | |------|------| | 1, 4 | 2.5 mg | | 5, 8 | 5 mg | | 9, 12 | 7.5 mg | | 13, 16 | 10 mg | | 17, 20 | 12.5 mg | | 21+ | 15 mg (maximum) |

Many women with PCOS do not need to reach 15 mg to see hormonal benefit. In the 2024 Fertility and Sterility cohort, the mean stabilization dose was 10 mg weekly, and meaningful androgen suppression was documented at doses as low as 7.5 mg [10]. Your prescriber may choose to hold the dose at a level that balances tolerability and effect rather than automatically pushing to the ceiling.

Injections are given subcutaneously in the abdomen, thigh, or upper arm. The day of the week should stay consistent. If a dose is missed by fewer than four days, take it as soon as possible; if more than four days have passed, skip that dose and resume on the regular schedule [11].

Dr. Ricardo Azziz, one of the researchers who helped establish the Rotterdam diagnostic criteria, has written: "Insulin sensitization remains the cornerstone of metabolic PCOS management, and weight reduction of 10% or more produces hormonal changes that no oral medication reliably replicates." [12]

Hormonal and Reproductive Outcomes: What to Monitor

Weight loss alone does not guarantee hormonal normalization, but tirzepatide's insulin-sensitizing effects appear to accelerate SHBG recovery beyond what calorie restriction alone produces. Here is what the available evidence suggests clinicians should track.

Androgens. Total testosterone and free androgen index typically begin declining within 8 to 12 weeks of starting tirzepatide, roughly coinciding with the first significant weight loss. In the 2024 observational cohort, free androgen index fell from a mean of 8.4 to 5.8 by month 3 [10].

SHBG. Rising SHBG is a direct marker of falling hepatic insulin exposure. A 44% rise over 6 months in the PCOS cohort [10] matches the pattern seen in bariatric surgery literature, which is considered the gold standard for obesity-related PCOS reversal.

LH/FSH ratio. An elevated LH/FSH ratio above 2:1 is a common finding in PCOS and often normalizes alongside weight loss. This ratio was not reported in the 2024 cohort study, and prospective data are needed.

Menstrual cycle regularity. This is the most patient-relevant endpoint. Cycle regularity does not require complete androgen normalization. In some women, a 10 to 15% weight reduction appears sufficient to restore ovulatory cycling, even before androgens return to the normal range [3].

Fertility considerations. Women who are not seeking pregnancy should be counseled that restored ovulation can occur before cycle regularity is obvious, meaning contraception should be discussed proactively. Women who are seeking fertility should discuss timing with a reproductive endocrinologist, because tirzepatide is not approved for use in pregnancy and should be discontinued at least two months before a planned conception attempt.

Side Effects Relevant to Women With PCOS

The gastrointestinal side-effect profile of tirzepatide is well-characterized. Nausea affected 17.4% of participants in SURMOUNT-1 at the 15 mg dose, vomiting affected 9.8%, and diarrhea affected 17.1% [9]. These rates are highest during the first four to eight weeks after each dose escalation and typically resolve.

For women with PCOS specifically, two additional considerations deserve attention.

First, because PCOS itself increases the risk of non-alcoholic fatty liver disease (NAFLD) by approximately 3-fold compared with BMI-matched controls, the hepatic benefits of tirzepatide are particularly relevant. A 2023 liver biopsy substudy in SURMOUNT-1 participants showed that tirzepatide reduced liver-fat content by a mean of 44% over 52 weeks [13].

Second, menstrual irregularity during early titration may be temporarily exacerbated in some women before it improves. Rapid weight loss, regardless of the mechanism, can transiently affect hypothalamic-pituitary-ovarian signaling. Cycles often normalize after the body adapts to a new weight set point, typically by month 3 or 4.

The black-box warning for tirzepatide covers medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN 2). In rodent studies, GLP-1 receptor agonists caused thyroid C-cell tumors at supratherapeutic exposures. Human relevance remains uncertain, but the contraindication stands. Women with a personal or family history of MTC or MEN 2 should not use tirzepatide [11].

Pancreatitis has been reported rarely. Women with PCOS who also have hypertriglyceridemia, a common comorbidity, carry a modestly elevated baseline risk of pancreatitis and should have a fasting lipid panel reviewed before starting treatment.

Comparing Tirzepatide to Other PCOS Treatments

Metformin remains the most commonly prescribed insulin sensitizer for PCOS and costs far less than tirzepatide. It reduces fasting insulin and may modestly improve cycle regularity, but its weight-loss effect is typically under 2 to 3 kg over 12 months. Tirzepatide produces ten times that weight loss in the same timeframe.

Semaglutide (Ozempic/Wegovy) is a GLP-1-only agonist that has more published PCOS-specific data than tirzepatide. The STEP-1 trial (N=1,961) showed 14.9% mean weight loss at 68 weeks [14]. Head-to-head, SURPASS-2 showed tirzepatide 15 mg outperformed semaglutide 1 mg on both A1C and weight, though the semaglutide dose used in that trial was the diabetes dose, not the obesity dose. A direct comparison at obesity-range doses has not been published.

Inositols (myo-inositol and D-chiro-inositol) are widely used as supplements for PCOS insulin resistance. A Cochrane review found they improve fasting insulin and androgen levels but the effect sizes are small and evidence quality is low [15]. They are not a replacement for pharmacotherapy in women with significant metabolic dysregulation.

Combined oral contraceptives address hyperandrogenism and regulate cycles but do not treat insulin resistance and may worsen it in some women. They are often co-prescribed alongside tirzepatide when cycle control and androgen suppression are needed while awaiting weight-loss-driven hormonal normalization.

Getting a Prescription: Insurance, Compounding, and Access

Tirzepatide is not FDA-approved for PCOS, which means insurance coverage is difficult unless a concurrent diagnosis of type 2 diabetes or obesity (BMI ≥30, or ≥27 with a weight-related comorbidity) is documented. Most commercial insurers follow FDA label indications. Without coverage, the list price of Mounjaro is approximately $1,060 per month, though the Lilly Savings Card can reduce out-of-pocket costs to $25/month for eligible commercially insured patients.

Women who meet criteria for Zepbound (tirzepatide for obesity) have a stronger insurance pathway, since obesity is a recognized comorbidity of PCOS and Zepbound received FDA approval for chronic weight management in November 2023. PCOS itself is listed as a qualifying weight-related comorbidity in the Zepbound label.

Telehealth prescribers, including HealthRX, can document the clinical indication thoroughly, which is the single most important factor in prior-authorization approval. A prior-authorization letter should include Rotterdam criteria documentation, fasting insulin or HOMA-IR value, body-weight trajectory, and prior treatment history with metformin or lifestyle interventions.

Compounded tirzepatide became widely available during the FDA shortage period. As of early 2025, the FDA removed tirzepatide from the drug shortage list, which means compounded versions from 503B outsourcing facilities are no longer legally permitted for most patients. Patients using compounded tirzepatide should discuss transitioning to the branded product with their provider.

How to Approach Your Provider

Bring objective data to the appointment. A printout of cycle tracking over the prior three months, a fasting insulin level, a lipid panel, and a total testosterone with SHBG gives your provider the foundation to document medical necessity accurately.

Ask specifically about Zepbound rather than Mounjaro if weight management is the primary documented indication, because the insurance pathway is cleaner. Both products contain tirzepatide at identical doses.

If your provider is unfamiliar with PCOS-specific tirzepatide use, the 2023 Endocrine Society guideline on obesity pharmacotherapy [4] and the 2024 Fertility and Sterility observational data [10] are reasonable starting points for a shared clinical discussion.

Baseline labs before starting should include: fasting glucose, HbA1c, fasting insulin, HOMA-IR, total testosterone, free androgen index, SHBG, LH, FSH, prolactin, TSH, ALT/AST, and a fasting lipid panel. Repeat the hormonal and metabolic panel at 3 and 6 months to document response and support continued prior-authorization requests.